Screener / SEC EDGAR /CIK 0001076930 /10-K filed Feb 23, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Technology · Miscellaneous Electrical Machinery, Equipment & Supplies

Novanta Inc NOVT

Compare with peers Embed
Earnings releases

Latest results release: Nov 9, 2026

8-K item 2.02, exhibit 99

What NOVT's management wrote with each quarter's results: the press release and, when the company files them, its prepared remarks or the call transcript. The call itself is not filed with SEC, so most quarters have the release only.

Adjusted vs GAAP earnings per share

In the company's own words · read from each release, never computed

In its release of Nov 9, 2026, NOVT reported $0.05 per share under GAAP and $1.05 on its own adjusted basis: the adjusted number is +2000% above GAAP.

GAAP EPS $0.35, release Feb 28, 2024: GAAP diluted earnings per share (“EPS”) was $0.35 in the fourth quarter of 2023, compared to $0.42 in the fourth quarter of 2022. Adjusted EPS $0.63, release Feb 28, 2024: Adjusted Diluted EPS was $0.63 in the fourth quarter of 2023, compared to $0.75 in the fourth quarter of 2022. +80% 2024-02 GAAP EPS $0.41, release May 7, 2024: 2024 GAAP Revenue of $231 million First Quarter 2024 GAAP Net Income of $15 million First Quarter 2024 GAAP Diluted Earnings Per Share of $0.41 First Quarter 2024 Adjusted Earnings Pe Adjusted EPS $0.74, release May 7, 2024: GAAP Net Income of $15 million First Quarter 2024 GAAP Diluted Earnings Per Share of $0.41 First Quarter 2024 Adjusted Earnings Per Share of $0.74 First Quarter 2024 Adjusted EBITDA of $ +80% 2024-05 GAAP EPS $0.38, release Aug 6, 2024: 2024 GAAP Revenue of $236 million Second Quarter 2024 GAAP Net Income of $13.8 million Second Quarter 2024 GAAP Diluted Earnings Per Share of $0.38 Second Quarter 2024 Adjusted Earnings P Adjusted EPS $0.73, release Aug 6, 2024: Net Income of $13.8 million Second Quarter 2024 GAAP Diluted Earnings Per Share of $0.38 Second Quarter 2024 Adjusted Earnings Per Share of $0.73 Second Quarter 2024 Adjusted EBITDA of +92% 2024-08 GAAP EPS $0.53, release Nov 5, 2024: 2024 GAAP Revenue of $244 million Third Quarter 2024 GAAP Net Income of $19 million Third Quarter 2024 GAAP Diluted Earnings Per Share of $0.53 Third Quarter 2024 Adjusted Earnings Pe Adjusted EPS $0.85, release Nov 5, 2024: GAAP Net Income of $19 million Third Quarter 2024 GAAP Diluted Earnings Per Share of $0.53 Third Quarter 2024 Adjusted Earnings Per Share of $0.85 Third Quarter 2024 Adjusted EBITDA of $ +60% 2024-11 GAAP EPS $0.46, release Feb 25, 2025: GAAP diluted earnings per share (“EPS”) was $0.46 in the fourth quarter of 2024, compared to $0.35 in the fourth quarter of 2023. Adjusted EPS $0.76, release Feb 25, 2025: Adjusted Diluted EPS increased 21% to $0.76 in the fourth quarter of 2024, compared to $0.63 in the fourth quarter of 2023. +65% 2025-02 GAAP EPS $0.59, release May 6, 2025: First Quarter 2025 GAAP Diluted Earnings Per Share of $0.59 and Adjusted EPS of $0.74 Adjusted EPS $0.74, release May 6, 2025: First Quarter 2025 GAAP Diluted Earnings Per Share of $0.59 and Adjusted EPS of $0.74 +25% 2025-05 GAAP EPS $0.12, release Aug 5, 2025: Second Quarter 2025 GAAP Diluted Earnings Per Share of $0.12 Adjusted EPS $0.76, release Aug 5, 2025: Second Quarter 2025 Adjusted EPS of $0.76 +533% 2025-08 GAAP EPS $0.30, release Nov 3, 2025: Third Quarter 2025 GAAP Diluted Earnings Per Share of $0.30 Adjusted EPS $0.87, release Nov 3, 2025: Third Quarter 2025 Adjusted EPS of $0.87 BOSTON, November 3, 2025 -- Novanta Inc. +190% 2025-11 GAAP EPS $0.45, release Feb 23, 2026: Fourth Quarter 2025 GAAP Revenue increased 9% to $258 million, and GAAP Diluted EPS was $0.45 Adjusted EPS $0.91, release Feb 23, 2026: Fourth Quarter 2025 Adjusted Diluted EPS was $0.91, increased 20%, and Adjusted EBITDA was $61 million, increased 17% +102% 2026-02 GAAP EPS $0.51, release May 11, 2026: First Quarter 2026 GAAP Diluted EPS was $0.51, and Adjusted Diluted EPS increased 9% to $0.81 BOSTON, May 11 , 2026 -- Novanta Inc. Adjusted EPS $0.81, release May 11, 2026: First Quarter 2026 GAAP Diluted EPS was $0.51, and Adjusted Diluted EPS increased 9% to $0.81 BOSTON, May 11 , 2026 -- Novanta Inc. +59% 2026-05 GAAP EPS $0.30, release Aug 5, 2026: Second Quarter 2026 GAAP Diluted EPS was $0.30, and Adjusted Diluted EPS increased 17% to $0.89 BOSTON, August 5 , 2026 -- Novanta Inc. Adjusted EPS $0.89, release Aug 5, 2026: Second Quarter 2026 GAAP Diluted EPS was $0.30, and Adjusted Diluted EPS increased 17% to $0.89 BOSTON, August 5 , 2026 -- Novanta Inc. +197% 2026-08 GAAP EPS $0.05, release Nov 9, 2026: Third Quarter 2026 GAAP Diluted EPS was $0.05, and Adjusted Diluted EPS increased 21% to $1.05 BOSTON, November 9, 2026 -- Novanta Inc. Adjusted EPS $1.05, release Nov 9, 2026: Third Quarter 2026 GAAP Diluted EPS was $0.05, and Adjusted Diluted EPS increased 21% to $1.05 BOSTON, November 9, 2026 -- Novanta Inc. +2000% 2026-11
GAAP EPSAdjusted EPS, as the company defines itThe figure on top is how far adjusted is from GAAP. Click a bar for the sentence.
The company's words, latest release
Third Quarter 2026 GAAP Diluted EPS was $0.05, and Adjusted Diluted EPS increased 21% to $1.05 BOSTON, November 9, 2026 -- Novanta Inc. release

What the company says its adjusted numbers leave out:

Adjusted Net Income Because Income Before Income Taxes is included in determining Net Income, the calculation of Adjusted Net Income also excludes amortization of acquired intangible assets, inventory acquisition fair value adjustments, operational transformation costs, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, officer transition costs, charges to achieve initial compliance with the EU Medical Device Regulation, and foreign exchange transaction gains (losses) for the reasons described above for Adjusted Income Before Income Taxes. release Nov 9, 2026

Both numbers are read from the words of each release (usually the highlights), never computed by us; hover a number for its sentence. Quarters where the release gives them only in a table are not shown. The company decides what "adjusted" leaves out; the full reconciliation is in the release.

Read and search

Every release, in full · linked to sec.gov

Press release Nov 9, 2026 · EX-99.1

Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial

Open on SEC

Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial Results for the Third Quarter 2026 • Third Quarter 2026 GAAP Revenue increased 23% to $305 million • Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted EBITDA increased 38% to $80 million • Third Quarter 2026 GAAP Diluted EPS was $0.05, and Adjusted Diluted EPS increased 21% to $1.05 BOSTON, November 9, 2026 -- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2026.

*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below. Third Quarter “The third quarter marked a significant milestone for Novanta as we closed the largest acquisition in our history and delivered strong financial results that exceeded our expectations,” said Matthijs Glastra, Chair and Chief Executive Officer. “Momentum continued in the third quarter as revenue advanced 23% and we achieved an Adjusted EBITDA margin of 26%, which improved 290 basis points year-over- year. Customer bookings increased 29%, reflecting strong commercial momentum and providing a solid foundation for future growth, expanding our backlog to $543 million. Equally important, Riverpoint Medical is performing in line with expectations as we continue to make meaningful progress on our operational synergies, while driving an exciting new product pipeline. Collectively, these results demonstrate the strength of our strategy and our continued commitment to driving sustainable growth and long-term shareholder value.” For the third quarter of 2026, Novanta generated GAAP revenue of $305 million, an increase of $57.2 million or 23.1%, compared to prior year. The Company’s acquisition activities resulted in a net increase in revenue of $32.9 million or 13.3%. Year-over-year changes in foreign currency exchange rates unfavorably impacted revenue by $0.3 million or -0.1%. Organic Revenue Growth, which excludes the net impact of changes in foreign currency exchange rates, was an increase of 9.9% (see “Organic Revenue Growth” in the non-GAAP reconciliations below). For the third quarter of 2026, GAAP operating income was $13.9 million, compared to $21.8 million in the prior year. GAAP net income was $2.0 million, compared to $10.7 million in the prior year. GAAP diluted earnings per share (“EPS”) was $0.05, compared to $0.30 in the prior year. Diluted weighted average shares outstanding was 42.7 million for the third quarter of 2026.

Adjusted Diluted EPS increased 20.7% to $1.05, compared to $0.87 in the prior year. Adjusted EBITDA increased 38.3% to $80.3 million, compared to $58.1 million in the prior year.

Operating cash flow was $39.3 million, compared to $8.5 million in the prior year. Year-to-date operating cash flow was $155.9 million compared to $55.3 million in the prior year.

Third quarter 2026 GAAP revenue was $145 million, as compared to $125 million in the same period a year ago.

Third quarter 2026 GAAP gross profit was $73 million, as compared to $59 million in the same period a year ago. GAAP Gross profit margins was 50.2% as a percentage of revenue, as compared to 47.3% in the same period a year ago.

Third quarter 2026 GAAP revenue was $160 million, as compared to $123 million in the same period a year ago.

Third quarter 2026 GAAP gross profit was $64 million, as compared to $53 million in the same period a year ago. GAAP Gross profit margins was 39.9% as a percentage of revenue, as compared to 43.0% in the same period a year ago.

“With strong year-to-date performance and continued momentum in customer bookings, we remain on track to deliver on our full year outlook of approximately 7% Organic Revenue Growth, (or 16% on a reported basis), more than 24% growth in Adjusted EBITDA, and approximately $200 million in operating cash flow,” said Matthijs Glastra, Chair and Chief Executive Officer. “Our strong backlog, new product contributions and leading positions in markets benefiting from favorable long-term secular trends provide a solid foundation for future growth and value creation. Looking ahead to 2027, we expect reported revenue growth of more than 15%.”

For the fourth quarter of 2026, the Company expects GAAP revenue to be in the range of $306 million to $312 million, reflecting reported revenue growth of more than 18%. The Company also expects Adjusted EBITDA to be in the range of $76 million to $79 million and Adjusted Diluted EPS to be in the range of $0.91 to $0.96 per diluted share, or 0% to 5% growth. The Company’s guidance assumes no significant changes in foreign exchange rates.

For the full year 2026, the Company now expects GAAP revenue to be in the range of $1,135 million to $1,140 million, reflecting reported growth of approximately 16%. The company expects Adjusted EBITDA to be in the range of $274 million to $277 million, and Adjusted Diluted EPS to be in the range of $3.66 to $3.71 per diluted share, or 11% to 13% growth. The Company’s guidance assumes no significant changes in foreign exchange rates.

Novanta provides earnings guidance, Gross Leverage, and Net Debt Leverage on a non-GAAP basis and does not provide earnings guidance, Gross Leverage, and Net Debt Leverage on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Organic Revenue Growth, Adjusted EBITDA, Adjusted Diluted EPS, Gross Leverage, and Net Debt Leverage guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; future changes in the fair value of contingent considerations; future restructuring expenses;

foreign exchange gains/(losses); significant discrete income tax expenses (benefits); benefits or expenses associated with the completion of tax audits; divestitures and related expenses; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non- GAAP Financial Measures” below. Conference Call Information The Company will host a conference call on Tuesday, November 10, 2026 at 8:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website atwww.novanta.com.

A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website atwww.novanta.com. The replay will remain available until Monday, December 28, 2026.

The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income, Adjusted Operating Margin, Adjusted Income Before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Net Debt, Gross Leverage and Net Debt Leverage.

The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisitions of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.

The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used to determine bonus payments for senior management and employees. The Company has also used in the past, and may use in the future, Adjusted Diluted EPS and Adjusted EBITDA as performance targets for certain performance-based restricted stock units. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.

Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “plan,” “aim,” “outlook,” and other similar expressions. These forward-looking statements include, but are not limited to, the statements of Mr. Glastra in this press release; statements regarding anticipated financial performance and financial position, including our financial outlook for the fourth quarter and full year 2026; expectations for our future growth and prospects; statements with respect to our backlog and our momentum; expectations for our customers and for our end markets; expectations for our strategy and business model; expectations for new product launches and commercial activities; expectations with respect to productivity enhancements; expectations for margin and cash flow performance; expectations for our site regionalization strategy; the financial contributions of the Riverpoint Medical acquisition to our future results of operations and financial condition, including our leverage ratio and other pro forma financial metrics; expectations regarding the anticipated benefits of the Riverpoint Medical acquisition, including its impact on revenue, profitability, addressable market, and manufacturing strategy; expectations for capital deployment to acquisitions or other investment options; expectations regarding our liquidity and capital resources, including our ability to fund the milestone payment related to the Riverpoint Medical acquisition; and other statements that are not historical facts.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various important factors, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our businesses and on our customers’ businesses, capital expenditures and level of business activities; our dependence upon our ability to respond to fluctuations in product demand; our ability to continuously innovate, to introduce new products in a timely manner, and to manage transitions to new product innovations effectively; customer order timing and the effect of order delays, cancellations or changes in customer demand and other similar factors; our ability to convert backlog into revenue; disruptions or breaches in security of our or our third-party providers’ information technology systems; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; our ability to contain or reduce costs; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business or to realize the anticipated benefits or synergies from those acquisitions; the accuracy of financial and other information regarding Riverpoint Medical on which we relied in connection with the acquisition and our related financial projections, which was not subject to the same accounting oversight and controls as our own historical financial information; our ability to accurately forecast Riverpoint Medical's future financial performance and our ability to maintain compliance with financial covenants under our credit facility, including our leverage ratio, which depends in part on the future financial performance of the combined company; our ability to fund the milestone payment related to the Riverpoint Medical acquisition when due; our ability to attract and retain key personnel; our restructuring and realignment activities; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers, including shortages and export restrictions; our failure to accurately forecast component and raw material requirements leading to additional costs and significant delays in shipments; production difficulties and product delivery delays or disruptions; our exposure to extensive medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products; the impacts of geopolitical conflicts on our business, including impacts relating to global supply chains, energy and commodity prices, financial markets and cybersecurity risks; potential penalties for violating foreign and U.S. federal and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations related to our business or products; actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards, and other requirements; our failure to implement new information technology systems successfully; changes in interest rates or foreign currency rates; our failure to realize the full value of our intangible assets; our reliance on original equipment manufacturer customers; the loss of sales, or significant reduction in orders from, any major customers; increasing scrutiny and changing expectations from investors, customers, governments and other stakeholders and third parties with respect to corporate

sustainability policies and practices; the effects of climate change and related regulatory responses; our exposure to the credit risk of some of our customers and in weakened markets; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as updated by our subsequent filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.

Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgical technologies with a proven ability to solve complex technical challenges. This enables Novanta to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation, the Novanta Growth System, and our customers’ success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website atwww.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 [email protected].

(781) 266-5137 NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands of U.S. dollars or shares, except per share amounts) (Unaudited)

Three Months Ended 2026 October 2, 2025 September 26, ────────────────────────────────────────────────────────────────────────────── Revenue $ 305,008 $ 247,836 Cost of revenue 169,370 136,915 Gross profit 135,638 110,921 Operating expenses: Research and development and 26,347 24,090 engineering Selling, general and 57,615 51,378 administrative Amortization of purchased 14,679 6,928 intangible assets Restructuring, acquisition, and 23,086 6,677 related costs Total operating 121,727 89,073 expenses Operating income 13,911 21,848 Interest income (8,284 ) (6,014 ) (expense), net Foreign exchange transaction 659 14 gains (losses), net Other income 60 (90 ) (expense), net Income before 6,346 15,758 income taxes Income tax provision 4,329 5,105 (benefit) Net Income $ 2,017 $ 10,653 Earnings per common share: Basic $ 0.05 $ 0.30 Diluted $ 0.05 $ 0.30 Weighted average common shares 42,590 35,967 outstanding—bas… Weighted average common shares 42,709 36,040 outstanding—dil…

ASSETS October 2, December 31, Current Assets 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash equivalents $ 149,218 $ 380,871 Accounts receivable, net 217,894 184,880 Inventories 220,368 188,284 Prepaid expenses and other current 34,784 28,566 assets Total current assets 622,264 782,601 Property, plant and 150,041 118,491 equipment, net Operating lease assets 55,140 41,697 Intangible assets, net 893,910 180,776 Goodwill 1,431,941 647,348 Other assets 19,750 36,193 Total assets $ 3,173,046 $ 1,807,106 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Current portion of $ 48,877 $ 38,291 long-term debt Accounts payable 99,304 94,865 Accrued expenses and other current 379,986 79,211 liabilities Total current liabilities 528,167 212,367 Long-term debt 780,949 212,538 Operating lease 49,960 38,873 liabilities Other long-term 189,461 29,041 liabilities Total liabilities 1,548,537 492,819 Stockholders’ Equity: Total stockholders’ equity 1,624,509 1,314,287 Total liabilities and stockholders’ $ 3,173,046 $ 1,807,106 equity

NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands of U.S. dollars) (Unaudited)

Three Months Cash flows from Ended operating October 2, September 26, activities: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net Income $ 2,017 $ 10,653 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 27,449 15,711 amortization Share-based 10,065 6,698 compensation Deferred income (5,572 ) (1,270 ) taxes Inventory acquisition 800 — fair value adjustments Other 1,748 1,706 Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions: Accounts (14,535 ) (10,175 ) receivable Inventories (2,029 ) (13,055 ) Other operating assets and 19,398 (1,773 ) liabilities Net cash provided by 39,341 8,495 operating activities Cash flows from investing activities: Cash paid for business acquisition, net (1,200,600 ) (1,118 ) of working capital adjustments Purchases of property, plant (8,966 ) (4,283 ) and equipment Proceeds from sale of 1,135 — property, plant and equipment Net cash used in investing (1,208,431 ) (5,401 ) activities Cash flows from financing activities: Borrowings under senior 626,000 — credit facilities Repayments of (25,311 ) (8,188 ) debt Proceeds from issuance of shares in private (428 ) — placement, net of issuance costs Payments of debt issuance (200 ) (452 ) costs Payments of withholding taxes from (395 ) (533 ) share-based awards Repurchases of — (14,056 ) common shares Other financing (214 ) (191 ) activities Net cash provided by and (used in) 599,452 (23,420 ) financing activities Effect of exchange rates on cash and 206 (365 ) cash equivalents Decrease in cash and cash (569,432 ) (20,691 ) equivalents Cash and cash equivalents, 718,650 109,912 beginning of period Cash and cash equivalents, $ 149,218 $ 89,221 end of period

NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands of U.S. dollars) (Unaudited) Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP):

Three Months Automation Ended Enabling October 2, September 26, Technologies 2026 2025 ────────────────────────────────────────────────────────────────────────────── Gross Profit $ 72,913 $ 59,214 (GAAP) Gross Profit 50.2 % 47.3 % Margin (GAAP) Amortization of intangible 1,143 1,473 assets Adjusted Gross Profit $ 74,056 $ 60,687 (Non-GAAP) Adjusted Gross Profit Margin 50.9 % 48.4 % (Non-GAAP) Medical Solutions Gross Profit $ 63,645 $ 52,697 (GAAP) Gross Profit 39.9 % 43.0 % Margin (GAAP) Amortization of intangible 5,586 2,779 assets Operational transformation 74 — costs Inventory acquisition fair 800 — value adjustments Adjusted Gross Profit $ 70,105 $ 55,476 (Non-GAAP) Adjusted Gross Profit Margin 43.9 % 45.3 % (Non-GAAP) Unallocated Gross Profit $ (920 ) $ (990 ) (GAAP) Adjusted Gross Profit $ (920 ) $ (990 ) (Non-GAAP) Novanta Inc. Gross Profit $ 135,638 $ 110,921 (GAAP) Gross Profit 44.5 % 44.8 % Margin (GAAP) Amortization of intangible 6,729 4,252 assets Operational transformation 74 — costs Inventory acquisition fair 800 — value adjustments Adjusted Gross Profit $ 143,241 $ 115,173 (Non-GAAP) Adjusted Gross Profit Margin 47.0 % 46.5 % (Non-GAAP)

NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in thousands except per share amounts) (Unaudited) Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in thousands except per share amounts) (Unaudited) Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP):

NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands of U.S. dollars) (Unaudited) Adjusted EBITDA (Non-GAAP):

Three Months Ended 2026 October 2, 2025 September 26, ────────────────────────────────────────────────────────────────────────────── Net Income $ 2,017 $ 10,653 (GAAP) Net Income 0.7 % 4.3 % Margin Interest (income) 8,284 6,014 expense, net Income tax provision 4,329 5,105 (benefit) Depreciation and 27,449 15,711 amortization Share-based 10,065 6,698 compensation Restructuring, acquisition and 22,243 6,156 related costs(1) Planning and design phase of the 3,686 3,519 financial and operation system implementation Operational transformation 921 — costs EU medical device 1,047 — regulation charges Costs incurred for insurance 221 3,042 recovery claim Inventory acquisition fair 800 — value adjustments Officer — 1,137 transition costs Other, net (719 ) 76 Adjusted EBITDA $ 80,343 $ 58,111 (Non-GAAP) Adjusted EBITDA Margin 26.3 % 23.4 % (Non-GAAP)

(1) This excludes the impact of depreciation and stock based compensation costs categorized as restructuring for the three months ended October 2, 2026 and September 26, 2025, of $0.8 million and $0.5 million, respectively. Organic Revenue Growth (Non-GAAP):

Three Months Ended October 2, 2026 ────────────────────────────────────────────────────────────────────────────── Compared to Three Months Ended September 26, 2025 Reported Revenue 23.1 % Growth/(Decline) (GAAP) Less: Change attributable to 13.3 % acquisitions Plus: Change due to foreign 0.1 % currency Organic Revenue Growth/(Decline) 9.9 % (Non-GAAP)

Non-GAAP Financial Measures The following provides additional explanations for non-GAAP financial measures used by the Company, including explanations for certain non-GAAP adjustments that may not be present in the quarterly disclosures included in the current earnings release but have been used by the Company in the two most recent fiscal years. See the tables above for the calculations of the non-GAAP financial measures used in this earnings release. Organic Revenue Growth The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees. Adjusted Gross Profit and Adjusted Gross Profit Margin The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin excludes amortization of acquired intangible assets and inventory acquisition fair value adjustments because: (i) the amounts are non-cash; (ii) the Company cannot influence the timing and amount of future expense recognition; and (iii) excluding such expenses provides investors and management better visibility into the underlying trends and performance of our businesses. The Company also excludes operational transformation costs as these costs occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.” Adjusted Operating Income and Adjusted Operating Margin The calculation of Adjusted Operating Income and Adjusted Operating Margin excludes amortization of acquired intangible assets, inventory acquisition fair value adjustments, and operational transformation costs for the reasons described above for Adjusted Gross Profit and Adjusted Gross Profit Margin. The Company also excludes restructuring costs, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, officer transition costs, and charges to achieve initial compliance with the EU Medical Device Regulation, as the significant charges have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.” Adjusted Income Before Income Taxes The calculation of Adjusted Income Before Income Taxes excludes amortization of acquired intangible assets, inventory acquisition fair value adjustments, operational transformation costs, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, officer transition costs, and charges to achieve initial compliance with the EU Medical Device Regulation for Adjusted Operating Income and Adjusted Operating Margin. The Company also excludes foreign exchange transaction gains (losses) as well as the write-off of costs related to our debt refinancing from the calculation of Adjusted Income Before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses).

Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income Before Income Taxes by jurisdiction, the applicable tax rates in effect for the respective jurisdictions and the income tax effect of non-GAAP adjustments discussed above. In addition, the Company excludes significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions not related to current year activity, tax audits, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate. Adjusted Net Income Because Income Before Income Taxes is included in determining Net Income, the calculation of Adjusted Net Income also excludes amortization of acquired intangible assets, inventory acquisition fair value adjustments, operational transformation costs, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, officer transition costs, charges to achieve initial compliance with the EU Medical Device Regulation, and foreign exchange transaction gains (losses) for the reasons described above for Adjusted Income Before Income Taxes. In addition, the Company excludes (i) significant discrete income tax expenses (benefits) related to releases of valuation allowances and uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (ii) the income tax effect of non-GAAP adjustments discussed above. Adjusted Diluted EPS Because Net Income is used in the calculation of Diluted EPS, Adjusted Diluted EPS excludes: (i) amortization of acquired intangible assets; (ii) inventory acquisition fair value adjustments; (iii) operational transformation costs; (iv) restructuring, acquisition and related costs; (v) discrete costs related to the planning and design phase of a financial and operation system implementation; (vi) charges related to an insurance recovery claim; (vii) charges to achieve initial compliance with the EU Medical Device Regulation; (viii) officer transition costs; (ix) foreign exchange transaction gains (losses); (x) significant discrete income tax expenses (benefits) related to releases of valuation allowances, uncertain tax positions, tax audits or amendments to prior year returns, certain changes in tax laws, and acquisition related tax planning actions on the Company’s effective tax rate; and (xi) the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted Net Income. Adjusted EBITDA and Adjusted EBITDA Margin The Company defines Adjusted EBITDA as income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, inventory acquisition fair value adjustments, restructuring, acquisition and related costs, discrete costs related to the planning and design phase of a financial and operation system implementation, charges related to an insurance recovery claim, operational transformation costs, charges to achieve initial compliance with the EU Medical Device Regulation, officer transition costs, and other non-operating (income) expense items, including foreign exchange transaction (gains) losses, costs related to our debt refinancing and net periodic pension costs of the Company’s frozen U.K. defined benefit pension plan for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.”

Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.

In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation. Free Cash Flow The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Management believes this non-GAAP financial measure is an important indicator of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth. Net Debt, Gross Leverage and Net Debt Leverage The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. We define Gross Leverage and Net Debt Leverage as the ratio of Total Debt and Net Debt to the last 12 months Adjusted EBITDA, which includes Adjusted EBITDA from acquisitions. Management believes Net Debt, Gross Leverage and Net Debt Leverage ratios are important measures to monitor our financial flexibility and evaluate the strength of our balance sheet. Net Debt, Gross Leverage and Net Debt Leverage ratios should not be considered in isolation or as a substitute for an analysis of our results prepared and presented in accordance with GAAP. * * * *

Full text with the tables
Exhibit 99.1 FOR IMMEDIATE RELEASE November 9, 2026 Novanta Announces Financial
Results
for the Third Quarter 2026 • Third Quarter 2026 GAAP Revenue increased 23% to
$305 million • Third Quarter 2026 GAAP Net Income was $2 million, and Adjusted
EBITDA increased 38% to $80 million • Third Quarter 2026 GAAP Diluted EPS was
$0.05, and Adjusted Diluted EPS increased 21% to $1.05 BOSTON, November 9, 2026
-- Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted
technology partner to medical and advanced technology equipment manufacturers,
today reported financial results for the third quarter 2026.
                                                                                
  Financial Highlights                                                          
  (In millions, except per   Three Months Ended                                 
  share amounts)             October 2,                   September 26,         
  GAAP                       2026                         2025                  
 ────────────────────────────────────────────────────────────────────────────── 
  Revenue                    $                   305.0    $              247.8  
  Operating Income           $                    13.9    $               21.8  
  Net Income                 $                     2.0    $               10.7  
  Diluted EPS                $                    0.05    $               0.30  
  Non-GAAP*                                                                     
  Adjusted Operating Income  $                    65.1    $               47.4  
  Adjusted Diluted EPS       $                    1.05    $               0.87  
  Adjusted EBITDA            $                    80.3    $               58.1  
                                                                                
*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions
for the non-GAAP financial measures included in this press release and the
reasons for their use, are presented below. Third Quarter “The third quarter
marked a significant milestone for Novanta as we closed the largest acquisition
in our history and delivered strong financial results that exceeded our
expectations,” said Matthijs Glastra, Chair and Chief Executive Officer.
“Momentum continued in the third quarter as revenue advanced 23% and we achieved
an Adjusted EBITDA margin of 26%, which improved 290 basis points year-over-
year. Customer bookings increased 29%, reflecting strong commercial momentum and
providing a solid foundation for future growth, expanding our backlog to $543
million. Equally important, Riverpoint Medical is performing in line with
expectations as we continue to make meaningful progress on our operational
synergies, while driving an exciting new product pipeline. Collectively, these
results demonstrate the strength of our strategy and our continued commitment to
driving sustainable growth and long-term shareholder value.” For the third
quarter of 2026, Novanta generated GAAP revenue of $305 million, an increase of
$57.2 million or 23.1%, compared to prior year. The Company’s acquisition
activities resulted in a net increase in revenue of $32.9 million or 13.3%.
Year-over-year changes in foreign currency exchange rates unfavorably impacted
revenue by $0.3 million or -0.1%. Organic Revenue Growth, which excludes the net
impact of changes in foreign currency exchange rates, was an increase of 9.9%
(see “Organic Revenue Growth” in the non-GAAP reconciliations below).
For the third quarter of 2026, GAAP operating income was $13.9 million, compared
to $21.8 million in the prior year. GAAP net income was $2.0 million, compared  
to $10.7 million in the prior year. GAAP diluted earnings per share (“EPS”) was 
$0.05, compared to $0.30 in the prior year. Diluted weighted average shares     
outstanding was 42.7 million for the third quarter of 2026.                     
                                                                                
Adjusted Diluted EPS increased 20.7% to $1.05, compared to $0.87 in the prior   
year. Adjusted EBITDA increased 38.3% to $80.3 million, compared to $58.1       
million in the prior year.                                                      
                                                                                
Operating cash flow was $39.3 million, compared to $8.5 million in the prior    
year. Year-to-date operating cash flow was $155.9 million compared to $55.3     
million in the prior year.                                                      
                                                                                
Financial Overview by Reporting Segment                                         
                                                                                
Automation Enabling Technologies                                                
                                                                                
Third quarter 2026 GAAP revenue was $145 million, as compared to $125 million in
the same period a year ago.                                                     
                                                                                
Third quarter 2026 GAAP gross profit was $73 million, as compared to $59 million
in the same period a year ago. GAAP Gross profit margins was 50.2% as a         
percentage of revenue, as compared to 47.3% in the same period a year ago.      
                                                                                
Medical Solutions                                                               
                                                                                
Third quarter 2026 GAAP revenue was $160 million, as compared to $123 million in
the same period a year ago.                                                     
                                                                                
Third quarter 2026 GAAP gross profit was $64 million, as compared to $53 million
in the same period a year ago. GAAP Gross profit margins was 39.9% as a         
percentage of revenue, as compared to 43.0% in the same period a year ago.      
                                                                                
Financial Guidance                                                              
                                                                                
“With strong year-to-date performance and continued momentum in customer        
bookings, we remain on track to deliver on our full year outlook of             
approximately 7% Organic Revenue Growth, (or 16% on a reported basis), more than
24% growth in Adjusted EBITDA, and approximately $200 million in operating cash 
flow,” said Matthijs Glastra, Chair and Chief Executive Officer. “Our strong    
backlog, new product contributions and leading positions in markets benefiting  
from favorable long-term secular trends provide a solid foundation for future   
growth and value creation. Looking ahead to 2027, we expect reported revenue    
growth of more than 15%.”                                                       
                                                                                
For the fourth quarter of 2026, the Company expects GAAP revenue to be in the   
range of $306 million to $312 million, reflecting reported revenue growth of    
more than 18%. The Company also expects Adjusted EBITDA to be in the range of   
$76 million to $79 million and Adjusted Diluted EPS to be in the range of $0.91 
to $0.96 per diluted share, or 0% to 5% growth. The Company’s guidance assumes  
no significant changes in foreign exchange rates.                               
                                                                                
For the full year 2026, the Company now expects GAAP revenue to be in the range 
of $1,135 million to $1,140 million, reflecting reported growth of approximately
16%. The company expects Adjusted EBITDA to be in the range of $274 million to  
$277 million, and Adjusted Diluted EPS to be in the range of $3.66 to $3.71 per 
diluted share, or 11% to 13% growth. The Company’s guidance assumes no          
significant changes in foreign exchange rates.                                  
                                                                                
Novanta provides earnings guidance, Gross Leverage, and Net Debt Leverage on a  
non-GAAP basis and does not provide earnings guidance, Gross Leverage, and Net  
Debt Leverage on a GAAP basis, with the exception of GAAP revenue guidance. A   
reconciliation of the Company’s forward-looking Organic Revenue Growth, Adjusted
EBITDA, Adjusted Diluted EPS, Gross Leverage, and Net Debt Leverage guidance to 
the most directly comparable GAAP financial measures is not provided because of 
the inherent difficulty in forecasting and quantifying certain amounts that are 
necessary for such reconciliations, including acquisitions and related expenses;
impact of purchase price allocations for recently completed acquisitions; future
changes in the fair value of contingent considerations; future restructuring    
expenses;                                                                       
                                                                                
foreign exchange gains/(losses); significant discrete income tax expenses       
(benefits); benefits or expenses associated with the completion of tax audits;  
divestitures and related expenses; gains and losses from sale of real estate    
assets; costs related to product line closures; intangible asset impairment     
charges and related asset write-offs; and other charges reflected in the        
Company’s reconciliation of historical non-GAAP financial measures, the amounts 
of which, based on past experience, could be material. For additional           
information regarding Novanta’s non-GAAP financial measures, see “Use of Non-   
GAAP Financial Measures” below.                                                 
Conference Call Information
The Company will host a conference call on Tuesday, November 10, 2026 at 8:00   
a.m. ET to discuss these results and to provide a business update. To access the
call, please dial (888) 346-3959 prior to the scheduled conference call time.   
Alternatively, the conference call can be accessed online via a live webcast on 
the Events & Presentations page of the Investors section of the Company’s       
website atwww.novanta.com.                                                      
                                                                                
A replay of the audio webcast will be available approximately three hours after 
the conclusion of the call in the Investor Relations section of the Company’s   
website atwww.novanta.com. The replay will remain available until Monday,       
December 28, 2026.                                                              
                                                                                
Use of Non-GAAP Financial Measures                                              
                                                                                
The non-GAAP financial measures used in this press release are Organic Revenue  
Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating 
Income, Adjusted Operating Margin, Adjusted Income Before Income Taxes, Adjusted
Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Net Income,     
Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow,  
Net Debt, Gross Leverage and Net Debt Leverage.                                 
                                                                                
The Company believes that these non-GAAP financial measures provide useful and  
supplementary information to investors regarding the operating performance of   
the Company. It is management’s belief that these non-GAAP financial measures   
would be particularly useful to investors because of the significant changes    
that have occurred outside of the Company’s day-to-day business in accordance   
with the execution of the Company’s strategy. This strategy includes            
streamlining the Company’s existing operations through site and functional      
consolidations, strategic divestitures and product line closures, expanding the 
Company’s business through significant internal investments, and broadening the 
Company’s product and service offerings through acquisitions of innovative and  
complementary technologies and solutions. The financial impact of certain       
elements of these activities, particularly acquisitions, divestitures, and site 
and functional restructurings, is often large relative to the Company’s overall 
financial performance and can adversely affect the comparability of its         
operating results and investors’ ability to analyze the business from period to 
period.                                                                         
                                                                                
The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Profit 
Margin are used by management to evaluate operating performance, communicate    
financial results to the Board of Directors, benchmark results against          
historical performance and the performance of peers, and evaluate investment    
opportunities, including acquisitions and divestitures. In addition, Adjusted   
EBITDA, Organic Revenue Growth and Adjusted Gross Profit Margin are used to     
determine bonus payments for senior management and employees. The Company has   
also used in the past, and may use in the future, Adjusted Diluted EPS and      
Adjusted EBITDA as performance targets for certain performance-based restricted 
stock units. Accordingly, the Company believes that these non-GAAP financial    
measures provide greater transparency and insight into management’s method of   
analysis.                                                                       
                                                                                
Non-GAAP financial measures should not be considered as substitutes for, or     
superior to, measures of financial performance prepared in accordance with GAAP.
They are limited in value because they exclude charges that have a material     
effect on the Company’s reported results and, therefore, should not be relied   
upon as the sole financial measures to evaluate the Company’s financial results.
The non-GAAP financial measures are meant to supplement, and to be viewed in    
conjunction with, GAAP financial measures. Investors are encouraged to review   
the reconciliation of these non-GAAP financial measures to their most directly  
comparable GAAP financial measures as provided in the tables accompanying this  
press release.                                                                  
                                                                                
Safe Harbor and Forward-Looking Information                                     
                                                                                
Certain statements in this release are “forward-looking statements” within the  
meaning of the Private Securities Litigation Reform Act of 1995 and are based on
current expectations and assumptions that are subject to risks and              
uncertainties. All statements contained in this news release that do not relate 
to matters of historical fact should be considered forward-looking statements,  
and are generally identified by words such as “expect,” “intend,” “anticipate,” 
“estimate,” “believe,” “future,” “target,” “could,” “should,” “may,” “plan,”    
“aim,” “outlook,” and other similar expressions. These forward-looking          
statements include, but are not limited to, the statements of Mr. Glastra in    
this press release; statements regarding anticipated financial performance and  
financial position, including our financial outlook for the fourth quarter and  
full year 2026; expectations for our future growth and prospects; statements    
with respect to our backlog and our momentum; expectations for our customers and
for our end markets; expectations for our strategy and business model;          
expectations for new product launches and commercial activities; expectations   
with respect to productivity enhancements; expectations for margin and cash flow
performance; expectations for our site regionalization strategy; the financial  
contributions of the Riverpoint Medical acquisition to our future results of    
operations and financial condition, including our leverage ratio and other pro  
forma financial metrics; expectations regarding the anticipated benefits of the 
Riverpoint Medical acquisition, including its impact on revenue, profitability, 
addressable market, and manufacturing strategy; expectations for capital        
deployment to acquisitions or other investment options; expectations regarding  
our liquidity and capital resources, including our ability to fund the milestone
payment related to the Riverpoint Medical acquisition; and other statements that
are not historical facts.                                                       
                                                                                
These forward-looking statements are neither promises nor guarantees, but       
involve risks and uncertainties that may cause actual results to differ         
materially from those contained in the forward-looking statements. Our actual   
results could differ materially from those anticipated in these forward-looking 
statements as a result of various important factors, including, but not limited 
to, the following: economic and political conditions and the effects of these   
conditions on our businesses and on our customers’ businesses, capital          
expenditures and level of business activities; our dependence upon our ability  
to respond to fluctuations in product demand; our ability to continuously       
innovate, to introduce new products in a timely manner, and to manage           
transitions to new product innovations effectively; customer order timing and   
the effect of order delays, cancellations or changes in customer demand and     
other similar factors; our ability to convert backlog into revenue; disruptions 
or breaches in security of our or our third-party providers’ information        
technology systems; risks associated with our operations in foreign countries;  
our increased use of outsourcing in foreign countries; risks associated with    
increased outsourcing of components manufacturing; our exposure to increased    
tariffs, trade restrictions or taxes on our products; our ability to contain or 
reduce costs; violations of our intellectual property rights and our ability to 
protect our intellectual property against infringement by third parties; risk of
losing our competitive advantage; our failure to successfully integrate recent  
and future acquisitions into our business or to realize the anticipated benefits
or synergies from those acquisitions; the accuracy of financial and other       
information regarding Riverpoint Medical on which we relied in connection with  
the acquisition and our related financial projections, which was not subject to 
the same accounting oversight and controls as our own historical financial      
information; our ability to accurately forecast Riverpoint Medical's future     
financial performance and our ability to maintain compliance with financial     
covenants under our credit facility, including our leverage ratio, which depends
in part on the future financial performance of the combined company; our ability
to fund the milestone payment related to the Riverpoint Medical acquisition when
due; our ability to attract and retain key personnel; our restructuring and     
realignment activities; product defects or problems integrating our products    
with other vendors’ products; disruptions in the supply of certain key          
components and other goods from our suppliers, including shortages and export   
restrictions; our failure to accurately forecast component and raw material     
requirements leading to additional costs and significant delays in shipments;   
production difficulties and product delivery delays or disruptions; our exposure
to extensive medical device regulations, which may impede or hinder the         
approval, certification or sale of our products and, in some cases, may         
ultimately result in an inability to obtain approval or certification of certain
products or may result in the recall or seizure of previously approved or       
certified products; the impacts of geopolitical conflicts on our business,      
including impacts relating to global supply chains, energy and commodity prices,
financial markets and cybersecurity risks; potential penalties for violating    
foreign and U.S. federal and state healthcare laws and regulations; impact of   
healthcare industry cost containment and healthcare reform measures; changes in 
governmental regulations related to our business or products; actual or         
perceived failures to comply with applicable data protection, privacy and       
security laws, regulations, standards, and other requirements; our failure to   
implement new information technology systems successfully; changes in interest  
rates or foreign currency rates; our failure to realize the full value of our   
intangible assets; our reliance on original equipment manufacturer customers;   
the loss of sales, or significant reduction in orders from, any major customers;
increasing scrutiny and changing expectations from investors, customers,        
governments and other stakeholders and third parties with respect to corporate  
                                                                                
sustainability policies and practices; the effects of climate change and related
regulatory responses; our exposure to the credit risk of some of our customers  
and in weakened markets; being subject to U.S. federal income taxation even     
though we are a non-U.S. corporation; changes in tax laws and fluctuations in   
our effective tax rates; any need for additional capital to adequately respond  
to business challenges or opportunities and repay or refinance our existing     
indebtedness, which may not be available on acceptable terms or at all; our     
existing indebtedness limiting our ability to engage in certain activities;     
volatility in the market price for our common shares; and our failure to        
maintain appropriate internal controls in the future.                           
                                                                                
Other important risk factors that could affect the outcome of the events set    
forth in these statements and that could affect the Company’s operating results 
and financial condition are discussed in Part I, Item 1A of our Annual Report on
Form 10-K for the fiscal year ended December 31, 2025, as updated by our        
subsequent filings with the Securities and Exchange Commission. Such statements 
are based on the Company’s beliefs and assumptions and on information currently 
available to the Company. The Company disclaims any obligation to publicly      
update or revise any such forward-looking statements as a result of developments
occurring after the date of this document except as required by law.            
                                                                                
About Novanta                                                                   
                                                                                
Novanta is a leading global supplier of core technology solutions that give     
medical, life science, and advanced industrial original equipment manufacturers 
a competitive advantage. We combine deep proprietary expertise and competencies 
in precision medicine, precision manufacturing, robotics and automation, and    
advanced surgical technologies with a proven ability to solve complex technical 
challenges. This enables Novanta to engineer proprietary technology solutions   
that deliver extreme precision and performance, tailored to our customers'      
demanding applications. The driving force behind our growth is the team of      
innovative professionals who share a commitment to innovation, the Novanta      
Growth System, and our customers’ success. Novanta’s common shares are quoted on
Nasdaq under the ticker symbol “NOVT.”                                          
                                                                                
More information about Novanta is available on the Company’s website            
atwww.novanta.com. For additional information, please contact Novanta Investor  
Relations at (781) 266-5137 [email protected].                    
                                                                                
Novanta Inc.                                                                    
                                                                                
Investor Relations Contact:                                                     
                                                                                
(781) 266-5137                                                                  
NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands of
U.S. dollars or shares, except per share amounts) (Unaudited)
                                                                                
                    Three Months                                                
                    Ended                                                       
                    2026               October 2,       2025  September 26,     
 ────────────────────────────────────────────────────────────────────────────── 
  Revenue           $                     305,008       $           247,836     
  Cost of revenue                         169,370                   136,915     
  Gross profit                            135,638                   110,921     
  Operating                                                                     
  expenses:                                                                     
  Research and                                                                  
  development and                          26,347                    24,090     
  engineering                                                                   
  Selling, general                                                              
  and                                      57,615                    51,378     
  administrative                                                                
  Amortization of                                                               
  purchased                                14,679                     6,928     
  intangible                                                                    
  assets                                                                        
  Restructuring,                                                                
  acquisition, and                         23,086                     6,677     
  related                                                                       
  costs                                                                         
  Total operating                         121,727                    89,073     
  expenses                                                                      
  Operating income                         13,911                    21,848     
  Interest income                          (8,284  )                 (6,014  )  
  (expense), net                                                                
  Foreign exchange                                                              
  transaction                                 659                        14     
  gains                                                                         
  (losses), net                                                                 
  Other income                                 60                       (90  )  
  (expense), net                                                                
  Income before                             6,346                    15,758     
  income taxes                                                                  
  Income tax                                                                    
  provision                                 4,329                     5,105     
  (benefit)                                                                     
  Net Income        $                       2,017       $            10,653     
  Earnings per                                                                  
  common share:                                                                 
  Basic             $                        0.05       $              0.30     
  Diluted           $                        0.05       $              0.30     
  Weighted average                                                              
  common shares                            42,590                    35,967     
  outstanding—bas…                                                              
  Weighted average                                                              
  common shares                            42,709                    36,040     
  outstanding—dil…                                                              
                                                                                
NOVANTA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands of U.S.
dollars) (Unaudited)
                                                                                
  ASSETS                      October 2,               December 31,             
  Current Assets              2026                     2025                     
 ────────────────────────────────────────────────────────────────────────────── 
  Cash and cash equivalents   $             149,218    $               380,871  
  Accounts receivable, net                  217,894                    184,880  
  Inventories                               220,368                    188,284  
  Prepaid expenses and other                                                    
  current                                    34,784                     28,566  
  assets                                                                        
  Total current assets                      622,264                    782,601  
  Property, plant and                       150,041                    118,491  
  equipment, net                                                                
  Operating lease assets                     55,140                     41,697  
  Intangible assets, net                    893,910                    180,776  
  Goodwill                                1,431,941                    647,348  
  Other assets                               19,750                     36,193  
  Total assets                $           3,173,046    $             1,807,106  
  LIABILITIES AND                                                               
  STOCKHOLDERS’ EQUITY                                                          
  Current Liabilities                                                           
  Current portion of          $              48,877    $                38,291  
  long-term debt                                                                
  Accounts payable                           99,304                     94,865  
  Accrued expenses and other                                                    
  current                                   379,986                     79,211  
  liabilities                                                                   
  Total current liabilities                 528,167                    212,367  
  Long-term debt                            780,949                    212,538  
  Operating lease                            49,960                     38,873  
  liabilities                                                                   
  Other long-term                           189,461                     29,041  
  liabilities                                                                   
  Total liabilities                       1,548,537                    492,819  
  Stockholders’ Equity:                                                         
  Total stockholders’ equity              1,624,509                  1,314,287  
  Total liabilities and                                                         
  stockholders’               $           3,173,046    $             1,807,106  
  equity                                                                        
                                                                                
NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands of
U.S. dollars) (Unaudited)
                                                                                
                   Three Months                                                 
  Cash flows from  Ended                                                        
  operating        October 2,                        September 26,              
  activities:      2026                              2025                       
 ────────────────────────────────────────────────────────────────────────────── 
  Net Income       $                     2,017       $               10,653     
  Adjustments to                                                                
  reconcile net                                                                 
  income to                                                                     
  net cash                                                                      
  provided by                                                                   
  operating                                                                     
  activities:                                                                   
  Depreciation                                                                  
  and                                   27,449                       15,711     
  amortization                                                                  
  Share-based                           10,065                        6,698     
  compensation                                                                  
  Deferred income                       (5,572  )                    (1,270  )  
  taxes                                                                         
  Inventory                                                                     
  acquisition                              800                            —     
  fair value                                                                    
  adjustments                                                                   
  Other                                  1,748                        1,706     
  Changes in                                                                    
  assets and                                                                    
  liabilities                                                                   
  which                                                                         
  (used)/provided                                                               
  cash,                                                                         
  excluding                                                                     
  effects from                                                                  
  business                                                                      
  acquisitions:                                                                 
  Accounts                             (14,535  )                   (10,175  )  
  receivable                                                                    
  Inventories                           (2,029  )                   (13,055  )  
  Other operating                                                               
  assets and                            19,398                       (1,773  )  
  liabilities                                                                   
  Net cash                                                                      
  provided by                           39,341                        8,495     
  operating                                                                     
  activities                                                                    
  Cash flows from                                                               
  investing                                                                     
  activities:                                                                   
  Cash paid for                                                                 
  business                                                                      
  acquisition,                                                                  
  net                               (1,200,600  )                    (1,118  )  
  of working                                                                    
  capital                                                                       
  adjustments                                                                   
  Purchases of                                                                  
  property, plant                       (8,966  )                    (4,283  )  
  and                                                                           
  equipment                                                                     
  Proceeds from                                                                 
  sale of                                1,135                            —     
  property, plant                                                               
  and equipment                                                                 
  Net cash used                                                                 
  in investing                      (1,208,431  )                    (5,401  )  
  activities                                                                    
  Cash flows from                                                               
  financing                                                                     
  activities:                                                                   
  Borrowings                                                                    
  under senior                         626,000                            —     
  credit                                                                        
  facilities                                                                    
  Repayments of                        (25,311  )                    (8,188  )  
  debt                                                                          
  Proceeds from                                                                 
  issuance of                                                                   
  shares in                                                                     
  private                                 (428  )                         —     
  placement, net                                                                
  of issuance                                                                   
  costs                                                                         
  Payments of                                                                   
  debt issuance                           (200  )                      (452  )  
  costs                                                                         
  Payments of                                                                   
  withholding                                                                   
  taxes from                              (395  )                      (533  )  
  share-based                                                                   
  awards                                                                        
  Repurchases of                             —                      (14,056  )  
  common shares                                                                 
  Other financing                         (214  )                      (191  )  
  activities                                                                    
  Net cash                                                                      
  provided by and                                                               
  (used in)                            599,452                      (23,420  )  
  financing                                                                     
  activities                                                                    
  Effect of                                                                     
  exchange rates                                                                
  on cash and                              206                         (365  )  
  cash                                                                          
  equivalents                                                                   
  Decrease in                                                                   
  cash and cash                       (569,432  )                   (20,691  )  
  equivalents                                                                   
  Cash and cash                                                                 
  equivalents,                         718,650                      109,912     
  beginning of                                                                  
  period                                                                        
  Cash and cash                                                                 
  equivalents,     $                   149,218       $               89,221     
  end of period                                                                 
                                                                                
NOVANTA INC. Revenue by Reportable Segment (In thousands of U.S. dollars)
(Unaudited)
                                                                                
                         Three Months Ended                                     
                         October 2,                     September 26,           
  Revenue                2026                           2025                    
 ────────────────────────────────────────────────────────────────────────────── 
  Automation Enabling    $                   145,355    $              125,316  
  Technologies                                                                  
  Medical Solutions                          159,653                   122,520  
  Total                  $                   305,008    $              247,836  
                                                                                
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands
of U.S. dollars) (Unaudited) Adjusted Gross Profit and Adjusted Gross Profit
Margin by Reportable Segment (Non-GAAP):
                                                                                
                    Three Months                                                
  Automation        Ended                                                       
  Enabling          October 2,                       September 26,              
  Technologies      2026                             2025                       
 ────────────────────────────────────────────────────────────────────────────── 
  Gross Profit      $                   72,913       $               59,214     
  (GAAP)                                                                        
  Gross Profit                            50.2  %                      47.3  %  
  Margin (GAAP)                                                                 
  Amortization of                                                               
  intangible                             1,143                        1,473     
  assets                                                                        
  Adjusted Gross                                                                
  Profit            $                   74,056       $               60,687     
  (Non-GAAP)                                                                    
  Adjusted Gross                                                                
  Profit Margin                           50.9  %                      48.4  %  
  (Non-GAAP)                                                                    
  Medical                                                                       
  Solutions                                                                     
  Gross Profit      $                   63,645       $               52,697     
  (GAAP)                                                                        
  Gross Profit                            39.9  %                      43.0  %  
  Margin (GAAP)                                                                 
  Amortization of                                                               
  intangible                             5,586                        2,779     
  assets                                                                        
  Operational                                                                   
  transformation                            74                            —     
  costs                                                                         
  Inventory                                                                     
  acquisition fair                         800                            —     
  value                                                                         
  adjustments                                                                   
  Adjusted Gross                                                                
  Profit            $                   70,105       $               55,476     
  (Non-GAAP)                                                                    
  Adjusted Gross                                                                
  Profit Margin                           43.9  %                      45.3  %  
  (Non-GAAP)                                                                    
  Unallocated                                                                   
  Gross Profit      $                     (920  )    $                 (990  )  
  (GAAP)                                                                        
  Adjusted Gross                                                                
  Profit            $                     (920  )    $                 (990  )  
  (Non-GAAP)                                                                    
  Novanta Inc.                                                                  
  Gross Profit      $                  135,638       $              110,921     
  (GAAP)                                                                        
  Gross Profit                            44.5  %                      44.8  %  
  Margin (GAAP)                                                                 
  Amortization of                                                               
  intangible                             6,729                        4,252     
  assets                                                                        
  Operational                                                                   
  transformation                            74                            —     
  costs                                                                         
  Inventory                                                                     
  acquisition fair                         800                            —     
  value                                                                         
  adjustments                                                                   
  Adjusted Gross                                                                
  Profit            $                  143,241       $              115,173     
  (Non-GAAP)                                                                    
  Adjusted Gross                                                                
  Profit Margin                           47.0  %                      46.5  %  
  (Non-GAAP)                                                                    
                                                                                
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in
thousands except per share amounts) (Unaudited) Adjusted Operating Income and
Adjusted Diluted EPS (Non-GAAP):
                                                                                
     T…                                                                         
     M…                                                                         
     E…                                                                         
     O…                                                                         
     2,                                                                         
     2…                                                                         
 ────────────────────────────────────────────────────────────────────────────── 
                            I…           I…                                     
     O…        O…           B…           T…        E…           N…       D…     
     I…        M…           I…           P…        T…           I…       E…     
                            T…           /         R…                           
                                         (…                                     
  …  $   1…        4…  %    $   6…       $   4…        6…  %    $   …    $   …  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      2…        7…  %        2…                                              
  …                                                                             
  …                                                                             
  …      3…        1…  %        3…                                              
  …                                                                             
  …                                                                             
  …      1…        6…  %        1…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      8…        0…  %        8…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      3…        1…  %        3…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      9…        0…  %        9…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…        0…  %        1…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      2…        0…  %        2…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                             (…  )                                           
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                          7…                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                          1…                                 
  …                                                                             
  …                                                                             
  …      5…        1…  %        5…           7…                     …        …  
  …                                                                             
  …                                                                             
  …  $   6…        2…  %    $   5…       $   1…        2…  %    $   …    $   …  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                          …  
  …                                                                             
  -                                                                             
  …                                                                             
                                                                                
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in
thousands except per share amounts) (Unaudited) Adjusted Operating Income and
Adjusted Diluted EPS (Non-GAAP):
                                                                                
     T…                                                                         
     M…                                                                         
     E…                                                                         
     S…                                                                         
     2…                                                                         
     2…                                                                         
 ────────────────────────────────────────────────────────────────────────────── 
                            I…           I…                                     
     O…        O…           B…           T…        E…           N…       D…     
     I…        M…           I…           P…        T…           I…       E…     
                            T…           /         R…                           
                                         (…                                     
  …  $   2…        8…  %    $   1…       $   5…        3…  %    $   …    $   …  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…        4…  %        1…                                              
  …                                                                             
  …                                                                             
  …      5…        2…  %        5…                                              
  …                                                                             
  …                                                                             
  …      1…        0…  %        1…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      3…        1…  %        3…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      3…        1…  %        3…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …      1…        0…  %        1…                                              
  …                                                                             
  …                                                                             
  …                                                                             
  …                             (…  )                                           
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                             
  …                                          4…                                 
  …                                                                             
  …                                                                             
  …                                                                             
  …                                          1…                                 
  …                                                                             
  …                                                                             
  …      2…        1…  %        2…           4…                     …        …  
  …                                                                             
  …                                                                             
  …  $   4…        1…  %    $   4…       $   9…        2…  %    $   …    $   …  
  …                                                                             
  …                                                                             
  …                                                                             
  …                                                                          …  
  …                                                                             
  -                                                                             
  …                                                                             
                                                                                
NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands
of U.S. dollars) (Unaudited) Adjusted EBITDA (Non-GAAP):
                                                                                
                    Three Months                                                
                    Ended                                                       
                    2026               October 2,       2025  September 26,     
 ────────────────────────────────────────────────────────────────────────────── 
  Net Income        $                       2,017       $            10,653     
  (GAAP)                                                                        
  Net Income                                  0.7  %                    4.3  %  
  Margin                                                                        
  Interest                                                                      
  (income)                                  8,284                     6,014     
  expense, net                                                                  
  Income tax                                                                    
  provision                                 4,329                     5,105     
  (benefit)                                                                     
  Depreciation and                         27,449                    15,711     
  amortization                                                                  
  Share-based                              10,065                     6,698     
  compensation                                                                  
  Restructuring,                                                                
  acquisition and                          22,243                     6,156     
  related                                                                       
  costs(1)                                                                      
  Planning and                                                                  
  design phase of                                                               
  the                                       3,686                     3,519     
  financial and                                                                 
  operation system                                                              
  implementation                                                                
  Operational                                                                   
  transformation                              921                         —     
  costs                                                                         
  EU medical                                                                    
  device                                    1,047                         —     
  regulation                                                                    
  charges                                                                       
  Costs incurred                                                                
  for insurance                               221                     3,042     
  recovery                                                                      
  claim                                                                         
  Inventory                                                                     
  acquisition fair                            800                         —     
  value                                                                         
  adjustments                                                                   
  Officer                                       —                     1,137     
  transition costs                                                              
  Other, net                                 (719  )                     76     
  Adjusted EBITDA   $                      80,343       $            58,111     
  (Non-GAAP)                                                                    
  Adjusted EBITDA                                                               
  Margin                                     26.3  %                   23.4  %  
  (Non-GAAP)                                                                    
                                                                                
(1) This excludes the impact of depreciation and stock based compensation costs
categorized as restructuring for the three months ended October 2, 2026 and
September 26, 2025, of $0.8 million and $0.5 million, respectively. Organic
Revenue Growth (Non-GAAP):
                                                                                
                                    Three Months Ended October 2,               
                                    2026                                        
 ────────────────────────────────────────────────────────────────────────────── 
                                    Compared to                                 
                                    Three Months Ended September 26,            
                                    2025                                        
  Reported Revenue                                                     23.1  %  
  Growth/(Decline) (GAAP)                                                       
  Less: Change attributable to                                         13.3  %  
  acquisitions                                                                  
  Plus: Change due to foreign                                           0.1  %  
  currency                                                                      
  Organic Revenue Growth/(Decline)                                      9.9  %  
  (Non-GAAP)                                                                    
                                                                                
Net Debt (Non-GAAP):
                                                                                
                                  2026  October 2,       2025  December 31,     
 ────────────────────────────────────────────────────────────────────────────── 
  Total Debt (GAAP)               $        829,826       $          250,829     
  Plus: Deferred financing costs             8,813                    8,726     
  Gross Debt                               838,639                  259,555     
  Less: Cash and cash                     (149,218  )              (380,871  )  
  equivalents                                                                   
  Net Debt (Non-GAAP)             $        689,421       $         (121,316  )  
                                                                                
Free Cash Flow (Non-GAAP):
                                                                                
                    Three Months                                                
                    Ended                                                       
                    2026               October 2,       2025  September 26,     
 ────────────────────────────────────────────────────────────────────────────── 
  Net Cash                                                                      
  Provided by                                                                   
  Operating         $                      39,341       $             8,495     
  Activities                                                                    
  (GAAP)                                                                        
  Less:                                                                         
  Purchases of                                                                  
  property, plant                          (8,966  )                 (4,283  )  
  and                                                                           
  equipment                                                                     
  Plus:                                                                         
  Proceeds from                                                                 
  sale of                                   1,135                         —     
  property, plant                                                               
  and equipment                                                                 
  Free Cash Flow    $                      31,510       $             4,212     
  (Non-GAAP)                                                                    
                                                                                
Non-GAAP Financial Measures                                                     
The following provides additional explanations for non-GAAP financial measures
used by the Company, including explanations for certain non-GAAP adjustments
that may not be present in the quarterly disclosures included in the current
earnings release but have been used by the Company in the two most recent fiscal
years. See the tables above for the calculations of the non-GAAP financial
measures used in this earnings release.
Organic Revenue Growth                                                          
The Company defines the term “organic revenue” as revenue excluding the impact
from business acquisitions, divestitures, product line discontinuations, and the
effect of foreign currency translation. The Company uses the related term
“organic revenue growth” to refer to the financial performance metric of
comparing current period organic revenue with the reported revenue of the
corresponding period in the prior year. The Company believes that this non-GAAP
financial measure, when taken together with our GAAP financial measures, allows
the Company and its investors to better measure the Company’s performance and
evaluate long-term performance trends. Organic revenue growth also facilitates
easier comparisons of the Company’s performance with prior and future periods
and relative comparisons to its peers. The Company excludes the effect of
foreign currency translation from these measures because foreign currency
translation is subject to volatility and can obscure underlying business trends.
The Company excludes the effect of acquisitions and divestitures because these
activities can vary dramatically between reporting periods and between the
Company and its peers, which the Company believes makes comparisons of long-term
performance trends difficult for management and investors. Organic Revenue
Growth is also used as a performance metric to determine bonus payments for
senior management and employees.
Adjusted Gross Profit and Adjusted Gross Profit Margin                          
The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin
excludes amortization of acquired intangible assets and inventory acquisition
fair value adjustments because: (i) the amounts are non-cash; (ii) the Company
cannot influence the timing and amount of future expense recognition; and (iii)
excluding such expenses provides investors and management better visibility into
the underlying trends and performance of our businesses. The Company also
excludes operational transformation costs as these costs occurred outside of the
Company’s day-to-day business for the reasons described above in the
introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted Operating Income and Adjusted Operating Margin                         
The calculation of Adjusted Operating Income and Adjusted Operating Margin
excludes amortization of acquired intangible assets, inventory acquisition fair
value adjustments, and operational transformation costs for the reasons
described above for Adjusted Gross Profit and Adjusted Gross Profit Margin. The
Company also excludes restructuring costs, acquisition and related costs,
discrete costs related to the planning and design phase of a financial and
operation system implementation, charges related to an insurance recovery claim,
officer transition costs, and charges to achieve initial compliance with the EU
Medical Device Regulation, as the significant charges have occurred outside of
the Company’s day-to-day business for the reasons described above in the
introductory paragraphs of the “Use of Non-GAAP Financial Measures.”
Adjusted Income Before Income Taxes                                             
The calculation of Adjusted Income Before Income Taxes excludes amortization of
acquired intangible assets, inventory acquisition fair value adjustments,
operational transformation costs, restructuring, acquisition and related costs,
discrete costs related to the planning and design phase of a financial and
operation system implementation, charges related to an insurance recovery claim,
officer transition costs, and charges to achieve initial compliance with the EU
Medical Device Regulation for Adjusted Operating Income and Adjusted Operating
Margin. The Company also excludes foreign exchange transaction gains (losses) as
well as the write-off of costs related to our debt refinancing from the
calculation of Adjusted Income Before Income Taxes as the Company cannot fully
influence the timing and amount of foreign exchange transaction gains (losses).

Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate

Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated
based on the Adjusted Income Before Income Taxes by jurisdiction, the applicable
tax rates in effect for the respective jurisdictions and the income tax effect
of non-GAAP adjustments discussed above. In addition, the Company excludes
significant discrete income tax expenses (benefits) related to releases of
valuation allowances and uncertain tax positions not related to current year
activity, tax audits, certain changes in tax laws, and acquisition related tax
planning actions on the Company’s effective tax rate.
Adjusted Net Income                                                             
Because Income Before Income Taxes is included in determining Net Income, the
calculation of Adjusted Net Income also excludes amortization of acquired
intangible assets, inventory acquisition fair value adjustments, operational
transformation costs, restructuring, acquisition and related costs, discrete
costs related to the planning and design phase of a financial and operation
system implementation, charges related to an insurance recovery claim, officer
transition costs, charges to achieve initial compliance with the EU Medical
Device Regulation, and foreign exchange transaction gains (losses) for the
reasons described above for Adjusted Income Before Income Taxes. In addition,
the Company excludes (i) significant discrete income tax expenses (benefits)
related to releases of valuation allowances and uncertain tax positions, tax
audits or amendments to prior year returns, certain changes in tax laws, and
acquisition related tax planning actions on the Company’s effective tax rate;
and (ii) the income tax effect of non-GAAP adjustments discussed above.
Adjusted Diluted EPS                                                            
Because Net Income is used in the calculation of Diluted EPS, Adjusted Diluted
EPS excludes: (i) amortization of acquired intangible assets; (ii) inventory
acquisition fair value adjustments; (iii) operational transformation costs; (iv)
restructuring, acquisition and related costs; (v) discrete costs related to the
planning and design phase of a financial and operation system implementation;
(vi) charges related to an insurance recovery claim; (vii) charges to achieve
initial compliance with the EU Medical Device Regulation; (viii) officer
transition costs; (ix) foreign exchange transaction gains (losses); (x)
significant discrete income tax expenses (benefits) related to releases of
valuation allowances, uncertain tax positions, tax audits or amendments to prior
year returns, certain changes in tax laws, and acquisition related tax planning
actions on the Company’s effective tax rate; and (xi) the income tax effect of
non-GAAP adjustments for the reasons described above for Adjusted Net Income.
Adjusted EBITDA and Adjusted EBITDA Margin                                      
The Company defines Adjusted EBITDA as income before deducting interest (income)
expense, income tax provision (benefit), depreciation, amortization, non-cash
share-based compensation, inventory acquisition fair value adjustments,
restructuring, acquisition and related costs, discrete costs related to the
planning and design phase of a financial and operation system implementation,
charges related to an insurance recovery claim, operational transformation
costs, charges to achieve initial compliance with the EU Medical Device
Regulation, officer transition costs, and other non-operating (income) expense
items, including foreign exchange transaction (gains) losses, costs related to
our debt refinancing and net periodic pension costs of the Company’s frozen U.K.
defined benefit pension plan for the reasons described above in the introductory
paragraphs of the “Use of Non-GAAP Financial Measures.”

Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue.

In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware
that in the future the Company may incur expenses that are the same as, or
similar to, some of the adjustments in this presentation.
Free Cash Flow                                                                  
The Company defines Free Cash Flow as net cash provided by operating activities
less cash paid for purchases of property, plant and equipment and plus cash
proceeds from sales of property, plant and equipment. Management believes this
non-GAAP financial measure is an important indicator of the Company’s liquidity
as well as its ability to service its outstanding debt and to fund future
growth.
Net Debt, Gross Leverage and Net Debt Leverage                                  
The Company defines Net Debt as its total debt as reported on the consolidated
balance sheet plus unamortized deferred financing costs and less its cash and
cash equivalents as of the end of the period presented. We define Gross Leverage
and Net Debt Leverage as the ratio of Total Debt and Net Debt to the last 12
months Adjusted EBITDA, which includes Adjusted EBITDA from acquisitions.
Management believes Net Debt, Gross Leverage and Net Debt Leverage ratios are
important measures to monitor our financial flexibility and evaluate the
strength of our balance sheet. Net Debt, Gross Leverage and Net Debt Leverage
ratios should not be considered in isolation or as a substitute for an analysis
of our results prepared and presented in accordance with GAAP.
                                    * * * *                                     

Sources

The 8-K item 2.02 filings (SEC EDGAR) and their EX-99 exhibits: the results release and, when filed, prepared remarks or the call transcript.

Also

Said vs did: the targets in these releases against what was then reported. Filings: every filing.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NOVT/export.csv") into a cell.

Next:Presentations
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.